FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely the application of differentiation factor as a method reducing the content of poorly differentiated cells and increasing the content of highly differentiated cells in human non-specific invasive breast carcinoma. Said factor is synthesized from a culture medium of human promyelocytic leukemic cell line HL-60 processed with retinoic acid with molecular mass of 8.2 kDa constituting a glycoprotein with a protein part corresponding with a molecular mass of 6.2 kDa having the following amino acid sequence: AGIMASLLKMLSAGPFVGWSQMIPFSDWPRRWHRLKELLTGENHRCGIFVINK.
EFFECT: invention allows effecing antineoplastic action not by destroying neoplastic cell but by transforming them; it does not effect cytotoxic action, particularly, does not cause escalation of degenerative-dystrophic changes, apoptosis, deterioration of membrane, protein and lipidic elements of the cells of the body.
2 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT REDUCING RELATIVE CONTENT OF LOW-DIFFERENTIATED CELLS AND INCREASING RELATIVE CONTENT OF HIGH-DIFFERENTIATED CELLS IN INVASIVE MAMMARY GLAND CARCINOMA OF NON-SPECIFIC TYPE | 2022 |
|
RU2786528C1 |
| COMPOSITION FOR INCREASING CONTENT OF HIGHLY DIFFERENTIATED CELLS IN BREAST ADENOCARCINOMA | 2018 |
|
RU2697199C1 |
| ANTIBODY RAISED TO HLDF, METHOD FOR IT PREPARING (VARIANTS), PEPTIDE SHOWING ANTIGENIC AND NUCLEIC ACID-HYDROLYZING PROPERTY AND METHOD FOR DIAGNOSIS OF HUMAN CELL ANAPLASTIC STATE | 2000 |
|
RU2276672C2 |
| METHOD FOR PREDICTION OF THE EFFECTIVENESS OF THE AGENT FOR INCREASING THE HIGH-DIFFERENTIATED CELLS IN MAMMARY ADENOCARCINOMA AND THE COMPOSITION FOR ITS IMPLEMENTATION | 2018 |
|
RU2705398C1 |
| RECOMBINANT Fab-scFv BASED ON A NEUTRALISING ANTIBODY AGAINST HUMAN BETA-1A INTERFERON AND AN ANTIBODY AGAINST HUMAN ErbB2 RECEPTOR | 2019 |
|
RU2748953C1 |
| METHOD OF PREDICTING HEMATOGENOUS METASTASIS IN INVASIVE CARCINOMA OF NONSPECIFIC TYPE OF MAMMARY GLAND BASED ON DETERMINATION OF DIFFERENT POPULATIONS OF CIRCULATING TUMOR CELLS IN BLOOD BEFORE TREATMENT | 2018 |
|
RU2678202C1 |
| METHOD FOR ACTIVATING CYTOTOXIC T-LYMPHOCYTES IN A POPULATION OF BLOOD MONONUCLEAR CELLS USING MEMBRANE VESICLES OBTAINED FROM GENETICALLY MODIFIED TUMOR CELLS OF M14 MELANOMA WITH OVEREXPRESSION OF INTERLEUKIN 2 | 2022 |
|
RU2790867C1 |
| USE OF RECOMBINANT ANALOGUE OF WATER-SOLUBLE DOMAIN OF LYNX1 PROTEIN FOR CELL GROWTH INHIBITION BY CARCINOMA | 2019 |
|
RU2721129C1 |
| DIAGNOSTIC TECHNIQUE FOR DEGREE OF THYROID CARCINOMA | 2011 |
|
RU2485517C2 |
| METHOD FOR QUANTITATIVE MEASUREMENT OF DIFFERENTIATION FACTOR THAT IS PROGNOSTIC BIOMARKER OF NORMAL AND PATHOLOGICAL INDIVIDUAL'S VASCULAR SYSTEM | 2013 |
|
RU2532381C1 |
